Barclays’s Mereo BioPharma MREO Stock Holding History

Barclays’s Portfolio MREO Stock Details MREO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$824	Sell	2,496 -12,004	-83%	-$5.15K	﹤0.01%	4913
2025 Q4	$6.04K	Buy	+14,500	New	+$27.6K	﹤0.01%	4973
2024 Q4	–	Sell	-38	Closed	-$156	–	5399
2024 Q3	$156	Hold	38	–	–	﹤0.01%	5173
2024 Q2	$137	Hold	38	–	–	﹤0.01%	4744
2024 Q1	$125	Hold	38	–	–	﹤0.01%	4992
2023 Q4	$88	Sell	38 -38	-50%	-$73	﹤0.01%	5172
2023 Q3	$98	Buy	76 +38	+100%	+$50	﹤0.01%	4547
2023 Q2	$50	Sell	38 -189,969	-100%	-$220K	﹤0.01%	4461
2023 Q1	$134K	Buy	190,007 +23,366	+14%	+$21K	﹤0.01%	4020
2022 Q4	$125K	Buy	166,641 +127,171	+322%	+$104K	﹤0.01%	4103
2022 Q3	$34K	Buy	39,470 +19,470	+97%	+$23.8K	﹤0.01%	3894
2022 Q2	$22K	Sell	20,000 -406,085	-95%	-$315K	﹤0.01%	4358
2022 Q1	$477K	Buy	426,085 +53,291	+14%	+$68.9K	﹤0.01%	2943
2021 Q4	$596K	Buy	372,794 +352,794	+1,764%	+$706K	﹤0.01%	3125
2021 Q3	$48K	Hold	20,000	–	–	﹤0.01%	4124
2021 Q2	$63K	Sell	20,000 -58,988	-75%	-$198K	﹤0.01%	4029
2021 Q1	$266K	Buy	+78,988	New	+$279K	﹤0.01%	3573
2019 Q3	–	Sell	-8	Closed	–	–	6976
2019 Q2	$0	Buy	+8	New	+$35	﹤0.01%	7120

Other funds holding MREO

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $712M AUM

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Barclays's MREO Position: Q1 2026 in Review

Barclays reduced its Mereo BioPharma (MREO) stake by 83% in Q1 2026, selling an estimated $5.15K and leaving 2,496 shares worth $824. The position accounts for ﹤0.01% of the portfolio, ranked #4913.

Barclays first reported a position in MREO in Q2 2019 and has held it in 18 quarters since. The position peaked at $596K in Q4 2021. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

Barclays held 2,496 shares of Mereo BioPharma worth $824 as of Q1 2026.
Barclays sold 12,004 Mereo BioPharma shares in Q1 2026, an estimated $5.15K.
Mereo BioPharma made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4913 holding.
Barclays first reported a position in Mereo BioPharma in Q2 2019 and has held it in 18 quarters since.
Barclays's Mereo BioPharma position peaked at $596K in Q4 2021.
63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.